美股异动 | 万春医药(BYSI.US)盘前涨逾7%，旗下抗癌药普那布林国际多中心3期研究达主要终点
© Reuters. 美股异动 | 万春医药(BYSI.US)盘前涨逾7%，旗下抗癌药普那布林国际多中心3期研究达主要终点
智通财经APP获悉，11月16日(周一)美股盘前，万春医药(BYSI.US)一度涨近15%，截至21：38，该股涨7.51%，报18.61美元。
万春医药宣布，普那布林与培非格司亭联合治疗在针对乳腺癌的国际多中心3期研究PROTECTIVE-2中的达到主要终点：联合治疗组和培非格司亭单药组中未发生4级中性粒细胞减少症(CIN)的患者百分比为31.5% Vs 13.6%。
此外，研究的所有关键次要终点也具有统计学意义，包括重度中性粒细胞减少症的持续时间(DSN)和中性粒细胞绝对计数(ANC)最小值。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.